MedTrace Logo

Afatinib Osimertinib Sequencing NIS

NCT03370770 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 204

Last updated 2020-12-24

Study results available
· View outcomes & findings →

Summary

This is a non-interventional, multi-country, multi-centre cohort study based on existing data from medical records of patients with EGFR mutation-positive advanced NSCLC treated with afatinib (Gi(l)otrif®) as the first-line treatment followed by osimertinib in case the T790M resistance mutation was developed.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Afatinib

GILOTRIF, GIOTRIF, XOVOLTIB

DRUG

Osimertinib

on T790M resistance mutation was developed

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-28
Primary Completion
2019-11-28
Completion
2019-11-28
FDA Drug
Yes

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03370770 on ClinicalTrials.gov